Why the study?
Does dalteparin (low-molecular-weight heparin) reduce deep venous thrombosis in patients in the acute phase of an ischemic stroke?
Population
60 patients in the acute phase of an ischemic stroke
Comparison
Dalteparin 2 x 2,500 anti-Xa units s.c./24 h vs Placebo
Design
RCT, randomized, double-blind, placebo-controlled
Authors
Loading...
Supports dalteparin for DVT prevention in acute ischemic stroke; confirms LMWH benefit but leaves safety open due to underpowering.
Does dalteparin (low-molecular-weight heparin) reduce deep venous thrombosis in patients in the acute phase of an ischemic stroke?
Low-molecular-weight heparin significantly reduces the frequency of DVT in acute ischemic stroke patients, though the study was underpowered to assess safety.
Prins et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: